Clinical trials: Advanced Rectal Cancers
DC-CIK Treatment, Regorafenib
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Research background and purpose: Patients with advanced colorectal cancer face the dilemma of limited treatment options and poor efficacy in the third line treatment stage.
- Conditions
- DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy
- Trial name
- NCT07343791
- Testing
- DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection
- Where
- China
- Volunteers
- 14 people
- Sponsor
- JIANG LONGWEI
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Rectal Cancer, Locally Advanced
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
A Single-arm phase II trial evaluating induction chemotherapy with FOLFIRINOXm followed by short course radiotherapy (RT) in locally advanced rectal carcinoma
- Trial name
- NCT05868317
- Testing
- Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy
- Where
- Tunisia
- Volunteers
- 70 people
- Sponsor
- Salah Azaïz Cancer Institute
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer
The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.
- Trial name
- sutent-capiri (NCT00777478)
- Testing
- capiri-sutent
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer, Cholangiocarcinoma
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
This study is being done to answer the following question: Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of…
- Trial name
- NCT04668976
- Testing
- Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Benaroya Research Institute
Rectal Cancer
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients.
- Trial name
- NCT03921684
- Testing
- Capecitabine, Radiation therapy, mFOLFOX6
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Baruch Brenner
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Colorectal Cancer, KRAS Wildtype
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful the combination of two drugs, panitumumab and trametinib, are in patients with advanced colorectal cancer with KRAS, NRAS, or…
- Conditions
- Colorectal Cancer, KRAS Wildtype, NRAS Wildtype, BRAF Wildtype
- Trial name
- NCT02399943
- Testing
- Trametinib, Panitumumab
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Rectal Carcinoma
IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment
RATIONALE: Using small radiation beamlets of different intensity, IMRT (intensity modulated radiation therapy) allows shaping the dose around planning target volume with better sparing of normal tissue comparing to 3D conformal…
- Trial name
- BISER (NCT02268006)
- Testing
- IMRT-SIB, Capecitabine, Surgery
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- Institute of Oncology Ljubljana
Locally Advanced Rectum Cancer
Predictive Value of 18F-FAZA in Rectum Cancer
The primary purpose of the study is to investigate 18F-FAZA-PETs role as predictor of response to neoadjuvant chemoradiation of locally advanced rectum cancer.
- Trial name
- FAZA (NCT01257035)
- Testing
- 18F-FAZA-PET/CT
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Vejle Hospital
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Low Rectal Cancer
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
This is an open-label, prospective, multicenter phase II clinical trial to evaluate modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with…
- Trial name
- mRCAT (NCT05972655)
- Testing
- Modified short-course radiotherapy, PD-1 antibody, Capecitabine
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sir Run Run Shaw Hospital
Rectal Cancer
Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
In patient with complete pathological response, surgery could be omitted without compromising progression-free or overall survival. A powerful prediction model is needed to guide management of this population.
- Trial name
- RECTOMICS (NCT04920435)
- Where
- 3 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Brest
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with…
- Trial name
- NCT04793958
- Testing
- MRTX849, Cetuximab, mFOLFOX6 Regimen
- Where
- 419 sites in United States, Argentina and 30 more
- Volunteers
- 461 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.